Advertisement

Biocompatibility, Biodistribution, and Drug-Delivery Efficiency of Mesoporous Silica Nanoparticles for Cancer Therapy in Animals

Authors

  • Jie Lu,

    1. California NanoSystems Institute, Department of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, 405 Hilgard Avenue, Los Angeles, California 90095 (USA)
    Search for more papers by this author
  • Monty Liong,

    1. California NanoSystems Institute, Department of Chemistry and Biochemistry, Jonsson Comprehensive Cancer Center, University of California Los Angeles, 405 Hilgard Avenue, Los Angeles, California 90095 (USA)
    Search for more papers by this author
  • Zongxi Li,

    1. California NanoSystems Institute, Department of Chemistry and Biochemistry, Jonsson Comprehensive Cancer Center, University of California Los Angeles, 405 Hilgard Avenue, Los Angeles, California 90095 (USA)
    Search for more papers by this author
  • Jeffrey I. Zink,

    1. California NanoSystems Institute, Department of Chemistry and Biochemistry, Jonsson Comprehensive Cancer Center, University of California Los Angeles, 405 Hilgard Avenue, Los Angeles, California 90095 (USA)
    Search for more papers by this author
  • Fuyuhiko Tamanoi

    Corresponding author
    1. California NanoSystems Institute, Department of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, 405 Hilgard Avenue, Los Angeles, California 90095 (USA)
    • California NanoSystems Institute, Department of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, 405 Hilgard Avenue, Los Angeles, California 90095 (USA).
    Search for more papers by this author

Abstract

Mesoporous silica nanoparticles (MSNs) are a promising material for drug delivery. In this Full Paper, MSNs are first shown to be well tolerated, as demonstrated by serological, hematological, and histopathological examinations of blood samples and mouse tissues after MSN injection. Biodistribution studies using human cancer xenografts are carried out with in vivo imaging and fluorescent microscopy imaging, as well as with inductively coupled plasma mass spectroscopy. The results show that MSNs preferentially accumulate in tumors. Finally, the drug-delivery capability of MSNs is demonstrated by following tumor growth in mice treated with camptothecin-loaded MSNs. These results indicate that MSNs are biocompatible, preferentially accumulate in tumors, and effectively deliver drugs to the tumors and suppress tumor growth.

Ancillary